Nanoparticle-mediated treatment of pulmonary arterial hypertension

Methods in Enzymology

Volumn 508, Issue , 2012, Pages 325-354

  Mosgoeller, W ^a   Prassl, R ^b   Zimmer, A ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Nanoparticles; Proticles; VIP

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; COPOLYMER; DRUG CARRIER; ILOPROST; LIPOSOME; MACROGOL; MICROSPHERE; NANOCRYSTAL; NANOPARTICLE; NANOPRECIPITATE; NIFEDIPINE; NITRIC OXIDE DONOR; OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; PEPTIDE DERIVATIVE; POLY(ETHYLENE GLYCOL) BLOCK LACTIDE GLYCOLIDE COPOLYMER; POLYETHYLENE OXIDE CO LACTIC ACID; POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; POLYVINYL ALCOHOL; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E1; PROTAMINE; PROTICLE; STEALTH LIPOSOME; TRANILAST; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; VASODILATOR AGENT;

ARTICLE; CONTINUOUS INFUSION; DENSITY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INHALER; LIGHT SCATTERING; MICELLE; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURFACE CHARGE;

EID: 84859033242     PISSN: 00766879     EISSN: 15577988     Source Type: Book Series    
DOI: 10.1016/B978-0-12-391860-4.00017-3     Document Type: Chapter

References (81)

1. R. Abu-Dahab, U.F. Schäfer, and C.M. Lehr Lectin-functionalized liposomes for pulmonary drug delivery: Effect of nebulization on stability and bioadhesion Eur. J. Pharm. Sci. 14 2001 37 46 (Pubitemid 32655413)
2. T.M. Allen, and P.R. Cullis Drug delivery systems: Entering the mainstream Science 303 2004 1818 1822 (Pubitemid 38374867)
3. R.J. Barst, S.I. Ertel, M. Beghetti, and D.D. Ivy Pulmonary arterial hypertension: A comparison between children and adults Eur. Respir. J. 37 2011 665 677
4. G.R. Bartlett Phosphorus assay in column chromatography J. Biol. Chem. 234 1959 466 468
5. A. Bergmann, G. Fritz, and O. Glatter Solving the generalized indirect Fourier transformation (GIFT) by Boltzmann simplex simulated annealing (BSSA) J. Appl. Cryst. 33 2000 1212 1216 (Pubitemid 32120465)
6. D.R. Bolin, J. Michalewsky, M.A. Wasserman, and M. O'Donnell Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma Biopolymers 37 1995 57 66
7. B. Burian, A. Storka, B.A. Marzluf, Y.C. Yen, C. Lambers, B. Robibaro, K. Vonbank, W. Mosgoeller, and V. Petkov Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients Peptides 31 2010 603 608
8. D.B. Buxton Nanomedicine for the management of lung and blood diseases Nanomedicine 4 2009 331 339
9. L.O. Cardell, O. Hjert, and R. Uddman The induction of nitric oxide-mediated relaxation of human isolated pulmonary arteries by PACAP Br. J. Pharmacol. 120 1997 1096 1100 (Pubitemid 27122649)
10. P. Couvreur, and C. Vauthier Nanotechnology: Intelligent design to treat complex disease Pharm. Res. 23 2006 1417 1450 (Pubitemid 43993807)
11. S. Dagar, M. Sekosan, B.S. Lee, I. Rubinstein, and H. Onyuksel VIP receptors as molecular targets of breast cancer: Implications for targeted imaging and drug delivery J. Control. Release 74 2001 129 134 (Pubitemid 32727615)
12. G.E. D'Alonzo Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann. Intern. Med. 115 1991 343 349
13. N. Düzgüne Preparation and quantitation of small unilamellar liposomes and large unilamellar reverse-phase evaporation liposomes Methods Enzymol. 367 2003 23 27
14. S.U. Egelhaaf, E. Wehrli, M. Müller, M. Adrian, and P. Schurtenberger Determination of the size distribution of lecithin liposomes: A comparative study using freeze fracture, cryoelectron microscopy and dynamic light scattering J. Microsc. 184 1996 214 228 (Pubitemid 27018905)
15. R. Ewert, S. Glaser, T. Bollmann, and C. Schaper Inhaled iloprost for therapy in pulmonary arterial hypertension Expert Rev. Respir. Med. 5 2011 145 152
16. R.F. Furchgott, and J.V. Zawadzki The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine Nature 288 1980 373 376 (Pubitemid 11169009)
17. X.P. Gao, Y. Noda, I. Rubinstein, and S. Paul Vasoactive intestinal peptide encapsulated in liposomes: Effects on systemic arterial blood pressure Life Sci. 54 1994 247 252 (Pubitemid 2062827)
18. M.P. George, H.C. Champion, and J.M. Pilewski Lung transplantation for pulmonary hypertension Pulm. Circ. 1 2011 182 191
19. K.K. Gill, S. Nazzal, and A. Kaddoumi Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: Formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation Eur. J. Pharm. Biopharm. 79 2011 276 284
20. G. Gololobov, Y. Noda, S. Sherman, I. Rubinstein, J. Baranowska- Kortylewicz, and S. Paul Stabilization of vasoactive intestinal peptide by lipids J. Pharmacol. Exp. Ther. 285 1998 753 758 (Pubitemid 28237458)
21. M. Gomberg-Maitland, and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur. Respir. J. 31 2008 891 901
22. V. Gupta, and F. Ahsan Inhalational therapy for pulmonary arterial hypertension: Current status and future prospects Crit. Rev. Ther. Drug Carrier Syst. 27 2010 313 370
23. V. Gupta, and F. Ahsan Influence of PEI as a core modifying agent on PLGA microspheres of PGE 1, a pulmonary selective vasodilator Int. J. Pharm. 413 2011 51 62
24. V. Gupta, A. Rawat, and F. Ahsan Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension J. Pharm. Sci. 99 2010 1774 1789
25. V. Gupta, M. Davis, L.J. Hope-Weeks, and F. Ahsan PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH) Pharm. Res. 28 2011 1733 1749
26. M.K. Haghighi, D. Pollock, and H.F. Hosseinei Vasorelaxant effects of atropine: Role of nitric oxide/ endothelium derived relaxing factor Indian J. Pharmacol. 34 2002 244 250 (Pubitemid 34918683)
27. F. Hajos, B. Stark, S. Hensler, R. Prassl, and W. Mosgoeller Inhalable liposomal formulation for vasoactive intestinal peptide Int. J. Pharm. 357 2008 286 294
28. M. Harada-Shiba Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats Mol. Ther. 17 2009 1180 1186
29. H.S. Jeh, S. Lu, and S.C. George Encapsulation of PROLI/NO in biodegradable microparticles J. Microencapsul. 21 2004 3 13 (Pubitemid 38180743)
30. Y. Kawabata, Y. Aoki, T. Matsui, K. Yamamoto, H. Sato, S. Onoue, and S. Yamada Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats Eur. J. Pharm. Biopharm. 77 2011 178 181
31. S. Kimura, K. Egashira, L. Chen, K. Nakano, E. Iwata, M. Miyagawa, H. Tsujimoto, K. Hara, R. Morishita, K. Sueishi, R. Tominaga, and K. Sunagawa Nanoparticle-mediated delivery of nuclear factor KB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension Hypertension 53 2009 877 883
32. E. Kleemann, T. Schmehl, T. Gessler, U. Bakowsky, T. Kissel, and W. Seeger Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: Formulation aspects and stability Pharm. Res. 24 2007 277 287 (Pubitemid 46072187)
33. K.S. Konduri, S. Nandedkar, D.A. Rickaby, N. Düzgüne, and P.R.J. Gangadharam The use of sterically stabilized liposomes to treat asthma Methods Enzymol. 391 2005 413 427 (Pubitemid 40254048)
34. N.R. Labiris, and M.B. Dolovich Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications Br. J. Clin. Pharmacol. 56 2003 600 612 (Pubitemid 37491711)
35. J. Liu Scanning transmission electron microscopy and its application to the study of nanoparticles and nanoparticle systems J. Electron Microsc. 54 2005 251 278 (Pubitemid 41628320)
36. D. Lochmann, J. Weyermann, C. Georgens, R. Prassl, and A. Zimmer Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: Physicochemical characterization Eur. J. Pharm. Biopharm. 59 2005 419 429 (Pubitemid 40342516)
37. H.M. Mansour, Y.S. Rhee, and X. Wu Nanomedicine in pulmonary delivery Int. J. Nanomedicine 4 2009 299 319
38. R. Morishita, J. Higaki, N. Tomita, and T. Ogihara Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease Circ. Res. 82 1998 1023 1028 (Pubitemid 28249063)
39. M.R. Mozafari Liposomes: An overview of manufacturing techniques Cell. Mol. Biol. Lett. 10 2005 711 719 (Pubitemid 43161695)
40. C. Mühlfeld, B. Rothen-Rutishauser, D. Vanhecke, F. Blank, P. Gehr, and M. Ochs Visualization and quantitative analysis of nanoparticles in the respiratory tract by transmission electron microscopy Part. Fibre Toxicol. 4 2007
41. H. Murakami, M. Kobayashi, H. Takeuchi, and Y. Kawashima Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method Int. J. Pharm. 187 1999 143 152 (Pubitemid 29443894)
42. S.T. Nadler, and J.D. Edelman Inhaled treprostinil and pulmonary arterial hypertension Vasc. Health Risk Manag. 6 2010 1115 1124
43. H. Olschewski Inhaled iloprost for severe pulmonary hypertension N. Engl. J. Med. 347 2002 322 329 (Pubitemid 34815354)
44. S. Onoue, Y. Aoki, Y. Kawabata, T. Matsui, K. Yamamoto, H. Sato, Y. Yamauchi, and S. Yamada Development of inhalable nanocrystalline solid dispersion of Tranilast for airway inflammatory diseases J. Pharm. Sci. 100 2011 622 633
45. H. Onyuksel, F. Sejourne, H. Suzuki, and I. Rubinstein Human VIP-alpha: A long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension Peptides 27 2006 2271 2275 (Pubitemid 44189611)
46. A. Ortner, K. Wernig, R. Kaisler, M. Edetsberger, F. Hajos, G. Köhler, W. Mosgoeller, and A. Zimmer VPAC receptor mediated tumor cell targeting by protamine based nanoparticles J. Drug Target. 18 2010 457 467
47. G. Pabst Global properties of biomimetic membranes: Perspectives on molecular features Biophys. Rev. Lett. 1 2006 57 84
48. G. Pabst, R. Koschuch, B. Pozo-Navas, M. Rappolt, K. Lohner, and P. Laggner Structural analysis of weakly ordered membrane stacks J. Appl. Cryst. 63 2003 1378 1388
49. H.I. Palevsky, B.L. Schloo, G.G. Pietra, K.T. Weber, J.S. Janicki, E. Rubin, and A.P. Fishman Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents Circulation 80 1989 1207 1221 (Pubitemid 19282509)
50. J.S. Patton, and P.R. Byron Inhaling medicines: Delivering drugs to the body through the lungs Nat. Rev. Drug Discov. 6 2007 67 74 (Pubitemid 46020287)
51. V. Petkov Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension J. Clin. Invest. 111 2003 1339 1346 (Pubitemid 36554704)
52. C. Plumley, E.M. Gorman, N. El-Gendy, C.R. Bybee, E.J. Munson, and C. Berkland Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy Int. J. Pharm. 369 2009 136 143
53. D.D. Rees, R.M. Palmer, H.F. Hodson, and S. Moncada A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation Br. J. Pharmacol. 96 1989 418 424 (Pubitemid 19045118)
54. I. Rubinstein Human VIP-alpha: An emerging biologic response modifier to treat primary pulmonary hypertension Expert Rev. Cardiovasc. Ther. 3 2005 565 569 (Pubitemid 41086817)
55. I. Rubinstein, M. Patel, H. Ikezaki, S. Dagar, and H. Onyuksel Conformation and vasoreactivity of VIP in phospholipids: Effects of calmodulin Peptides 20 1999 1497 1501 (Pubitemid 30069896)
56. I. Rubinstein, H. Ikezaki, and H. Onyuksel Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters Int. J. Pharm. 316 2006 144 147 (Pubitemid 43765699)
57. M. Sakagami In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery Adv. Drug Deliv. Rev. 58 2006 1030 1060 (Pubitemid 44712023)
58. F. Sejourne, I. Rubinstein, H. Suzuki, and H. Alkan-Onyuksel Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes Pharm. Res. 14 1997 362 365 (Pubitemid 27160951)
59. V. Sethi, H. Onyuksel, and I. Rubinstein Liposomal vasoactive intestinal peptide Methods Enzymol. 391 2005 377 395 (Pubitemid 40254046)
60. O.A. Shlobin, and S.D. Nathan Pulmonary hypertension secondary to interstitial lung disease Expert Rev. Respir. Med. 5 2011 179 189
61. M. Smola, T. Vandamme, and A. Sokolowski Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases Int. J. Nanomedicine 3 2008 1 19 (Pubitemid 351517072)
62. B. Stark, P. Debbage, F. Andreae, W. Mosgoeller, and R. Prassl Association of vasoactive intestinal peptide with polymer-grafted liposomes: Structural aspects for pulmonary delivery Biochim. Biophys. Acta 1768 2007 705 714 (Pubitemid 46275600)
63. B. Stark, F. Andreae, W. Mosgoeller, M. Edetsberger, E. Gaubitzer, G. Koehler, and R. Prassl Liposomal vasoactive intestinal peptide for lung application: Protection from proteolytic degradation Eur. J. Pharm. Biopharm. 70 2008 153 164
64. C.S. Stevenson, and M.A. Birrell Moving towards a new generation of animal models for asthma and COPD with improved clinical relevance Pharmacol. Ther. 130 2011 93 105
65. H. Suzuki, Y. Noda, S. Paul, X.P. Gao, and I. Rubinstein Encapsulation of vasoactive intestinal peptide into liposomes: Effects on vasodilation in vivo Life Sci. 57 1995 1451 1457
66. D.I. Svergun Determination of the regularization parameter in indirect-transform methods using perceptual criteria J. Appl. Cryst. 25 1992 495 503 (Pubitemid 23564996)
67. M. Thomas, J.J. Lu, Q. Ge, C. Zhang, J. Chen, and A.M. Klibanov Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung Proc. Natl. Acad. Sci. USA 102 2005 5679 5684 (Pubitemid 40559619)
68. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160 (Pubitemid 40282557)
69. V.P. Torchilin Multifunctional nanocarriers Adv. Drug Deliv. Rev. 58 2006 1532 1555 (Pubitemid 44822608)
70. V. Torchilin Multifunctional and stimuli-sensitive pharmaceutical nanocarriers Eur. J. Pharm. Biopharm. 71 2009 431 444
71. R. Tulloh Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension Paediatr. Drugs 11 2009 115 128
72. C.A. Wagenvoort, and N. Wagenvoort Primary pulmonary hypertension: A pathological study of the lung vessel in 156 clinically diagnosed cases Circulation 42 1970 1163 1184
73. V. Wagner, A. Dullaart, A.K. Bock, and A. Zweck The emerging nanomedicine landscape Nat. Biotechnol. 24 2006 1211 1217 (Pubitemid 44564760)
74. J.C. Waldrep, B.E. Gilbert, C.M. Knight, M.B. Black, P.W. Scherer, V. Knight, and W. Eschenbacher Pulmonary delivery of beclomethasone liposome aerosol in volunteers - Tolerance and safety Chest 111 1997 316 323 (Pubitemid 27096944)
75. K. Wernig, M. Griesbacher, F. Andreae, F. Hajos, J. Wagner, W. Mosgoeller, and A. Zimmer Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles J. Control. Release 130 2008 192 198
76. J. Weyermann, D. Lochmann, and A. Zimmer A practical note on the use of cytotoxicity assays Int. J. Pharm. 288 2005 369 376 (Pubitemid 40038590)
77. J. Weyermann, D. Lochmann, C. Georgens, and A. Zimmer Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: Cellular uptake and effect Eur. J. Pharm. Biopharm. 59 2005 431 438 (Pubitemid 40342517)
78. P. Wood Pulmonary hypertension with special reference to the vasoconstrictive factor Br. Heart J. 20 1958 557 570
79. D. Wu, D. Lee, and Y.K. Sung Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: A review Respir. Res. 12 2011 45
80. H. Yeshua, L.M. Blendis, and R. Oren Pulmonary manifestations of liver diseases Semin. Cardiothorac. Vasc. Anesth. 13 2009 60 69
81. E. Zakynthinos, Z. Daniil, J. Papanikolaou, and D. Makris Pulmonary hypertension in COPD: Pathophysiology and therapeutic targets Curr. Drug Targets 12 2011 501 513